DERM News and Press, Journey Medical Corporation From 03/13/24

SCOTTSDALE, Ariz., March 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment ...

Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that DFD-29 can be safely used for up to 16 weeks with no detectable effects on microbiota in the skin, GI tract, or vagina New Drug A...

2024-01-05 09:20:37 ET More on Journey Medical, Dr. Reddy's, etc. The Strategic Evolution Of Journey Medical In Dermatological Care Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements Journey Medical Corporation (DERM) Q3 2023 Earni...

If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea NDA submission supported by positive Phase 3 clinical data SCOTTSDALE, Ariz., Jan. 05, 2024 (GLOBE NEWSWIRE) --  Journey...

2024-01-02 16:19:57 ET More on Journey Medical The Strategic Evolution Of Journey Medical In Dermatological Care Journey Medical Corporation (DERM) Q3 2023 Earnings Call Transcript Top 10 stocks under $10, as ranked by SA's Quant Ratings Journey Medical direc...

SCOTTSDALE, Ariz., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (&#x...

2023-12-26 10:02:19 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tu...

2023-12-12 19:21:37 ET Summary Celestica's stock initially dipped after its third quarter earnings report in October, but the "Strong Buy" quant score prevailed and shares rebounded. Stock rating among its peer comparisons reviewed. The company's strong Q3 results, including i...

2023-12-08 16:53:34 ET Summary Journey Medical shows a meteoric rise, led by strategic focus on dermatology and product innovation. Despite challenges, DFD-29, an oral treatment for rosacea, shows promise, potentially revolutionizing moderate to severe cases. Q3 2023 financial...

SCOTTSDALE, Ariz., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (&#x...